Citations

Clear

3314 citation(s) found for "Yu, Alexander".

The EP3662 clone of CD1a supports the diagnosis of New World cutaneous leishmaniasis
Hammond, Alexander M. , Kallis, Penelope , Sokumbi, Olayemi , Auerbach, Jena, Vincek, Vladimir , Kallis, Penelope J , Motaparthi, Kiran , Sokumbi, Olayemi

Mayo Clinic

Journal of Cutaneous Pathology | March 6, 2021 | Volume: 48 | Issue: 10 | Pages: 1317-1320

10.1111/cup.14001 | PMID 33675546 Get It

A framework for living evidence synthesis in cancer: Living, interactive network meta-analysis for first-line treatment of metastatic renal cell carcinoma (mRCC).
Ryu, Alexander J. , Naqvi, Syed Arsalan Ahmed , Maheswari, Deepa, Sipra, Qurat Ul Ain Riaz , Pagliaro, Lance C. , Costello, Brian A. , Riaz, Irbaz Bin , He, Huan , Ryu, Alexander J. , Siddiqi, Rabbia , Yao, Yuan , Husnain, Muhammad , Montori, Víctor M. , Joseph, Richard W. , Liu, Hongfang , Wang, Zhen , Herasevich, Vitaly , Singh, Parminder Pal , Ho, Thai H. , Bryce, Alan H. , Murad, M. Hassan

Mayo Clinic

Journal of Clinical Oncology | March 2, 2021 | Volume: 39 | Issue: 6_suppl | Pages: 335-335

10.1200/jco.2021.39.6_suppl.335 Get It

335 Background: Systematic reviews are outdated quickly when the evidence is rapidly evolving as the process is laborious and there is little incentive for primary author team of an index SRMA to update the evidence. Consequently, there is an epidemic of redundant SRMAs performed by different teams—sometimes with conflicted results—for treatment of first line mRCC. Methods: We have created a living, interactive systematic review (LISR)and network meta-analysis(LINMA) for the treatment of first line mRCC using an Artificial intelligence (AI) assisted framework for evidence synthesis (Living, Interactive evidence synthesis framework) (LIvE) . The framework is implemented in five-layered architecture (application layer, shared module layer, core service layer, middleware layer, and storage layer) which work together to automate the identification of new studies and analysis and semi-automate the screening and data extraction. Dynamic features such as interactive tables, figures and evidence maps are enabled using Python and JavaScript programming languages. Results: We have maintained a living, interactive evidence profile for the first line treatment mRCC since September 2019 ( LIVING WEBSITE) . Living search strategy identifies new studies as they become available. As of October 13, 2020 LISR, includes data 14 clinical trials ( PRISMA ). Baseline characteristics are summarized in an interactive table ( TABLE) . Cabozantinib& Nivolumab (Cabo-Nivo) is the highest ranked drug for improving Overall Response (OR), Progression Free Survival (PFS) and Overall Survival (OS) whereas Ipilimumab in combination with Nivolumab (Ipi-Nivo) is highest ranked drug for achieving complete response (CR). Ipi-Nivo and Atezolizumab & Bevacizumab (Ate-Bev) ranked highest and Cabo-Nivo ranked lowest for treatment related Adverse events (TRAEs). Results of network meta-analysis are summarized as interactive tables and plots ( NMA ), summary of findings tables ( MULTIPLE COMAPRISONS ) and evidence maps ( MAP ). Conclusions: LISRs can potentially reduce redundancy, increase transparency, reproducibility, enable shared-decision making (at a guideline level, or in a patient-clinician dyad) and support living guidelines.
Multi-Omics Data Analysis of Gene Expressions and Alterations, Cancer-Associated Fibroblast and Immune Infiltrations, Reveals the Onco-Immune Prognostic Relevance of STAT3/CDK2/4/6 in Human Malignancies
Lawal, Bashir , Lin, Li-Ching, Lee, Jih-Chin, Chen, Jia‐Hong , Bekaii‐Saab, Tanios , Wu, Alexander T.H. , Ho, Ching-Liang, Bekaii-Saab, Tanios S , Wu, Alexander T H , Lee, Jih‐Chin , Chen, Jia-Hong , Ho, Ching‐Liang

Mayo Clinic

Cancers | February 25, 2021 | Volume: 13 | Issue: 5 | Pages: 954

10.3390/cancers13050954 | PMID 33668805 Get It

Signal transducer and activator of transcription 3 (STAT3)/Cyclin-dependent kinases are multifunctional proteins that play an important implicative role in cancer initiations, progression, drug resistance, and metastasis, and has been extensively explored in cancer therapy. However, the genetic alterations of STAT3/CDK2/4/6 and its role in predicting immune infiltration and immunotherapeutic response are yet to be well exploited. In this study, we use in silico methods to analyze differential expression, prognostic value, genetic and epigenetic alterations, association with tumor-infiltrating immune cells, and cancer-associated fibroblast (CAF) infiltrations of STAT3/CDK2/4/6 in multiple cancer types. Our results revealed that the expression of STAT3/CDK2/4/6 was altered in various cancers and is associated with poor overall and disease-free survival of the cohorts. Moreover, genetic alterations in STAT3/CDK2/4/6 co-occurred with a number of other genetic alterations and are associated with poorer prognoses of the cohorts. The protein-protein interaction (PPI) network analysis suggests CDK2/4/6/STAT3 may directly interact with factors that promote tumorigenesis and immune response. We found that STAT3/CDK2/4/6 expressions were associated with infiltrations of CAF and the various immune cells in multiple cancers and it’s associated with poor response to immunotherapy. Collectively, our study suggested that STAT3/CDK2/4/6 are important onco-immune signatures that play central roles in tumor immune invasion, poor prognoses and, immune therapy response. Findings from the present study may therefore be clinically useful in prognosis assessment and follow-up management of immunotherapy.
Reducing Alarm Burden in a Level IV Neonatal Intensive Care Unit
McCauley, Kortany, Schroeder, Alissa A., DeBoth, Tawney K., Wiebe, Alexander M., Bosley, Christopher L., Ballweg, Diane D., Fang, Jennifer L. , McCauley, Kortany E, Bosley, Christopher

Mayo Clinic

Pediatric Quality & Safety | February 25, 2021 | Volume: 6 | Issue: 2 | Pages: e386

10.1097/pq9.0000000000000386 | PMID 38571516 Get It

Introduction: Excessive alarm burden contributes to alarm fatigue, causing staff to ignore or delay response to clinically significant alarms. The objective of this quality improvement project was to reduce yellow self-resolving SpO2 alarms from a mean of 14 alarms/patient-hour (APH) to 7 APH (a 50% reduction) within a 6-month period, without significantly decreasing the amount of time spent in target SpO2 range (90%–95%). Methods: A multidisciplinary team used Define-Measure-Analyze-Improve-Control methodology to identify etiologies of alarm frequency and design improvement interventions to reduce alarm burden in a single-site Level IV NICU. Data-driven changes in alarm limit settings, alarm delay, and trial of a new pulse oximeter probe were used. Alarm data from the bedside monitor were analyzed following each improvement cycle. As a balancing measure, histograms monitored time spent in target SpO2 range. Results: SpO2 alarm data were collected for 4,320 patient-hours (180 patient-days) on 40 neonatal intensive care unit patients meeting inclusion criteria. Corresponding histograms were obtained for each patient day. Following 5 Plan-Do-Study-Act cycles, the mean number of yellow self-resolving SpO2 alarms decreased from 14 to 5 APH, a 64% decrease. There was no difference in time spent in target SpO2 range (50% versus 50%, P = 0.93). After achieving the project aim, 2 control phase measurements demonstrated sustained improvement (mean APH = 6). Conclusions: Yellow self-resolving SpO2 alarm frequency was reduced by 64% through the implementation of data-driven changes in alarm limit settings, alarm delays, and trial of a more sensitive oximeter probe without introducing harm to patients.
Association of Social Determinants of Health with Time to Diagnosis and Treatment Outcomes in Idiopathic Subglottic Stenosis
Lee, Jaclyn , Huang, Li‐Ching , Berry, Lynn D., Anderson, Catherine , Amin, Milan R. , Benninger, Michael S. , Blumin, Joel H. , Bock, Jonathan M. , Bryson, Paul C. , Castellanos, Paul F., Chen, Sheau‐Chiann , Cohen, Seth M. , Crawley, Brianna K. , Dailey, Seth H. , Daniero, James J. , Alarcón, Alessandro de , Donovan, Donald T., Edell, Eric S. , Ekbom, Dale C. , Fink, Daniel S. , Franco, Ramon A. , Garrett, C. Gaelyn , Hoffman, Henry T. , Hogikyan, Norman D. , Howell, Rebecca J. , Hussain, Lena K., Johns, Michael M. , Kasperbauer, Jan L. , Khosla, Sid , Kinnard, Cheryl, Kupfer, Robbi A. , Langerman, Alexander , Lentz, Robert J. , Lorenz, Robert R. , Lowery, Anne S. , Makani, Samir, Maldonado, Fabien , Matrka, Laura , McWhorter, Andrew J., Meratı, Albert L., Mori, Matthew , O’Dell, Karla , Ongkasuwan, Julina , Postma, Gregory N. , Reder, Lindsay , Richardson, Brent E. , Rickman, Otis B. , Rosen, Clark A. , Rutter, Michael J. , Sandhu, Guri, Schindler, Joshua S. , Schneider, Glenn Todd , Shah, Rupali N., Sikora, Andrew G. , Sinard, Robert J. , Smith, Marshall E. , Smith, Libby J. , Soliman, Ahmed M. S. , Sveinsdóttir, Sigríður, Daele, Douglas J. Van , Veivers, David , Verma, Sunil P., Weissbrod, Philip A. , Wootten, Christopher T. , Shyr, Yu , Francis, David O. , Cohen, Seth M , Dailey, Seth H , Hoffman, Henry T , Lott, David G , Mori, Matthew , Ongkasuwan, Julian , Richardson, Brent E , Gelbard, Alexander , Chen, Sheau-Chiann , Weissbrod, Philip A , Clary, Matthew S. , Guardiani, Elizabeth , Hillel, Alexander T. , Lott, David G. , Mannion, Kyle , Netterville, James L. , Rohde, Sarah L. , Weinberger, Paul , Gelbard, Alexander , Amin, Milan R

Mayo Clinic

Annals of Otology, Rhinology & Laryngology | February 25, 2021 | Volume: 130 | Issue: 10 | Pages: 1116-1124

10.1177/0003489421995283 | PMID 33629608 Get It

Objectives: To examine whether social determinants of health (SDH) factors are associated with time to diagnosis, treatment selection, and time to recurrent surgical intervention in idiopathic subglottic stenosis (iSGS) patients. Methods: Adult patients with diagnosed iSGS were recruited prospectively (2015-2017) via clinical providers as part of the North American Airway Collaborative (NoAAC) and via an online iSGS support community on Facebook. Patient-specific SDH factors included highest educational attainment (self-reported), median household income (matched from home zip code via U.S. Census data), and number of close friends (self-reported) as a measure of social support. Main outcomes of interest were time to disease diagnosis (years from symptom onset), treatment selection (endoscopic dilation [ED] vs cricotracheal resection [CTR] vs endoscopic resection with adjuvant medical therapy [ERMT]), and time to recurrent surgical intervention (number of days from initial surgical procedure) as a surrogate for disease recurrence. Results: The total 810 participants were 98.5% female, 97.2% Caucasian, and had a median age of 50 years (IQR, 43-58). The cohort had a median household income of $62 307 (IQR, $50 345-$79 773), a median of 7 close friends (IQR, 4-10), and 64.7% of patients completed college or graduate school. Education, income, and number of friends were not associated with time to diagnosis via multivariable linear regression modeling. Univariable multinominal logistic regression demonstrated an association between education and income for selecting ED versus ERMT, but no associations were noted for CTR. No associations were noted for time to recurrent surgical procedure via Kaplan Meier modeling and Cox proportional hazards regression. Conclusions: Patient education, income, and social support were not associated with time to diagnosis or time to disease recurrence. This suggests additional patient, procedure, or disease-specific factors contribute to the observed variations in iSGS surgical outcomes.
Busulfan-based reduced toxicity conditioning regimen used in hematopoietic stem cell transplantation in HLH patients results in sustained donor chimerism
Goode, Erin , Miller, Holly, Salzberg, Dana, Beebe, Kristen , Schwalbach, Charlotte , Adams, Roberta H. , Ngwube, Alexander , Ngwube, Alexander , Campbell, Courtney

Mayo Clinic

Pediatric Hematology and Oncology | February 24, 2021 | Volume: 38 | Issue: 4 | Pages: 410-416

10.1080/08880018.2020.1868638 | PMID 33625293 Get It

3D Printing for Complex Cranial Surgery Education: Technical Overview and Preliminary Validation Study
Graffeo, Christopher S. , Perry, Avital , Carlstrom, Lucas P. , Peris‐Celda, Maria , Alexander, Amy E. , Dickens, Hunter J., Holroyd, Michael J., Driscoll, Colin L. W., Link, Michael J., Alexander, Amy, Link, Michael J. , Morris, Jonathan M.

Mayo Clinic

Journal of Neurological Surgery Part B: Skull Base | February 23, 2021 | Volume: 83 | Issue: S 02 | Pages: e105-e112

10.1055/s-0040-1722719 | PMID 35832942 Get It

Abstract Background 3D printing—also known as additive manufacturing—has a wide range of applications. Reproduction of low-cost, high-fidelity, disease- or patient-specific models presents a key developmental area in simulation and education research for complex cranial surgery. Methods Using cadaveric dissections as source materials, skull base models were created, printed, and tested for educational value in teaching complex cranial approaches. In this pilot study, assessments were made on the value of 3D printed models demonstrating the retrosigmoid and posterior petrosectomy approaches. Models were assessed and tested in a small cohort of neurosurgery resident subjects (n = 3) using a series of 10 radiographic and 2 printed case examples, with efficacy determined via agreement survey and approach selection accuracy. Results All subjects indicated agreement or strong agreement for all study endpoints that 3D printed models provided significant improvements in understanding of neuroanatomic relationships and principles of approach selection, as compared to 2D dissections or patient cross-sectional imaging alone. Models were not superior to in-person hands-on teaching. Mean approach selection accuracy was 90% (±13%) for 10 imaging-based cases, or 92% (±7%) overall. Trainees strongly agreed that approach decision-making was enhanced by adjunctive use of 3D models for both radiographic and printed cases. Conclusion 3D printed models incorporating skull base approaches and/or pathologies provide a compelling addition to the complex cranial education armamentarium. Based on our preliminary analysis, 3D printed models offer substantial potential for pedagogical value as dissection guides, adjuncts to preoperative study and case preparation, or tools for approach selection training and evaluation.
A mobile unit overcomes the challenges to monoclonal antibody infusion for COVID‐19 in skilled care facilities
Tulledge‐Scheitel, Sidna M. , Bell, Sarah, Larsen, Jennifer J., Bierle, Dennis M. , Moehnke, Darcie E. , Borgen, Molly J. Destro, Springer, Donna J., Reinschmidt, Karen J. , Baumbach, Lori J., Matoush, Jennifer A., Heyliger, Alexander , Hanson, Sara N. , Ganesh, Ravindra , Tulledge-Scheitel, Sidna, Bell, Sarah J. , Takahashi, Paul, Destro Borgen, Molly J, Razonable, Raymund R , Ganesh, Ravindra , Takahashi, Paul Y. , Razonable, Raymund R.

Mayo Clinic

Journal of the American Geriatrics Society | February 22, 2021 | Volume: 69 | Issue: 4 | Pages: 868-873

10.1111/jgs.17090 | PMID 33619724 Get It

Abstract Background Residents of nursing homes and long‐term care facilities are at increased risk for severe coronavirus disease‐19 (COVID‐19) but may not be able to access monoclonal antibody therapies offered at outpatient infusion centers due to frailty and logistical issues. We describe a mobile monoclonal antibody infusion program for patients with COVID‐19 in skilled nursing facilities and provide descriptive data on its outcomes. Design Retrospective cohort study. Setting Collaboration between Mayo Clinic and skilled nursing facilities in Southeast Minnesota was developed to administer anti‐spike monoclonal antibodies under the FDA Emergency Use Authorization. Participants Seventy five residents of skilled nursing facilities at high risk of COVID‐19 complications. Exposure Emergency use treatment with bamlanivimab and casirivimab–imdevimab. Measurements Hospitalization and medically attended visits. Results The mobile infusion unit, staffed by Mayo Clinic Infusion Therapy registered nurses and supported by the skilled nursing facility staff, infused anti‐spike monoclonal antibodies to 45 of 75 patients (average age, 77.8 years) in December 2020. The infusions occurred at an average of 4.3 days after COVID‐19 diagnosis. Fourteen days after infusion, there were no deaths, two emergency department visits, and three hospitalizations, for a combined event rate of 11.1%. There was one reported adverse event. Conclusion The implementation of a mobile infusion unit embedded in a collaborative process resulted in rapid infusion of monoclonal antibodies to high‐risk COVID‐19 patients in skilled nursing facilities, who would otherwise be unable to access the novel therapies. The therapies were well tolerated and appear beneficial. Further study is warranted to explore the scalability and efficacy of this program.
GAS7 Deficiency Promotes Metastasis in MYCN-Driven Neuroblastoma
Dong, Zhiwei , Yeo, Kok Siong , Eggum, Erin N. Dankert , Rokita, Jo Lynne , Ung, Choong Yong , Levee, Taylor M., Her, Zuag Paj , Howe, Cassie J., Hou, Xiaonan , Ree, Janine H. van, Li, Shuai , He, Shuning , Fritchie, Karen , Torres‐Mora, Jorge , Lehman, Julia S. , Meves, Alexander , Razidlo, Gina L. , Rathi, Komal S. , Weroha, S. John , Look, A. Thomas , Deursen, Jan M. van , Zhu, Shizhen , Lopez, Gonzalo , Dankert Eggum, Erin N, Rokita, Jo Lynne , van Ree, Janine H, Tao, Ting , Torres-Mora, Jorge, Razidlo, Gina L , Look, A Thomas , Maris, John M , Zhu, Shizhen , Lehman, Julia S , Dankert, Erin N. , Zhang, Cheng , Tao, Ting , Li, Hu , Westendorf, Jennifer J. , Maris, John M.

Mayo Clinic

Cancer Research | February 18, 2021 | Volume: 81 | Issue: 11 | Pages: 2995-3007

10.1158/0008-5472.can-20-1890 | PMID 33602789 Get It

Abstract One of the greatest barriers to curative treatment of neuroblastoma is its frequent metastatic outgrowth prior to diagnosis, especially in cases driven by amplification of the MYCN oncogene. However, only a limited number of regulatory proteins that contribute to this complex MYCN-mediated process have been elucidated. Here we show that the growth arrest-specific 7 (GAS7) gene, located at chromosome band 17p13.1, is preferentially deleted in high-risk MYCN-driven neuroblastoma. GAS7 expression was also suppressed in MYCN-amplified neuroblastoma lacking 17p deletion. GAS7 deficiency led to accelerated metastasis in both zebrafish and mammalian models of neuroblastoma with overexpression or amplification of MYCN. Analysis of expression profiles and the ultrastructure of zebrafish neuroblastoma tumors with MYCN overexpression identified that GAS7 deficiency led to (i) downregulation of genes involved in cell–cell interaction, (ii) loss of contact among tumor cells as critical determinants of accelerated metastasis, and (iii) increased levels of MYCN protein. These results provide the first genetic evidence that GAS7 depletion is a critical early step in the cascade of events culminating in neuroblastoma metastasis in the context of MYCN overexpression. Significance: Heterozygous deletion or MYCN-mediated repression of GAS7 in neuroblastoma releases an important brake on tumor cell dispersion and migration to distant sites, providing a novel mechanism underlying tumor metastasis in MYCN-driven neuroblastoma. See related commentary by Menard, p. 2815
Comparative effectiveness of oral anticoagulants in everyday practice
Camm, A. John , Virdone, Saverio , Bassand, Jean‐Pierre , Fitzmaurice, David , Berchuck, Samuel I. , Goldhaber, Samuel Z. , Goto, Shinya , Haas, Sylvia , Misselwitz, Frank , Pieper, Karen S. , Turpie, Alexander G.G., Cappato, Riccardo , Kakkar, Ajay K. , Verheugt, Freek W A , Fox, Keith A.A. , Gersh, Bernard J. , Turpie, Alexander G.G., Verheugt, Freek W.A.

Mayo Clinic

Heart | February 17, 2021 | Volume: 107 | Issue: 12 | Pages: 962-970

10.1136/heartjnl-2020-318420 | PMID 33593994 Get It

Objectives This study evaluated the comparative effectiveness of vitamin K antagonists (VKAs), direct thrombin inhibitors (DTIs) and factor Xa inhibitors (FXaI) in patients with atrial fibrillation (AF) at risk of stroke in everyday practice. Methods Data from patients with AF and Congestive heart failure, Hypertension, Age 75 years, Diabetes mellitus, prior Stroke, TIA, or thromboembolism, Vascular disease, Age 65-74 years, Sex category (CHA2DS2-VASc) score ≥2 (excluding gender) in the Global Anticoagulant Registry in the FIELD–Atrial Fibrillation registry were analysed using an improved method of propensity weighting, overlap weights and Cox proportional hazards models. Results All-cause mortality, non-haemorrhagic stroke/systemic embolism (SE) and major bleeding over 2 years were compared in 25 551 patients, 7162 (28.0%) not treated with oral anticoagulant (OAC) and 18 389 (72.0%) treated with OAC (FXaI (41.8%), DTI (11.4%) and VKA (46.8%)). OAC treatment compared with no OAC treatment was associated with decreased risk of all-cause mortality (HR 0.82 (95% CI 0.74 to 0.91)) and non-haemorrhagic stroke/SE (HR 0.71 (95% CI 0.57 to 0.88)) but increased risk of major bleeding (HR 1.46 (95% CI 1.15 to 1.86)). Non-vitamin K antagonist oral anticoagulant (NOAC) use compared with no OAC treatment was associated with lower risks of all-cause mortality and non-haemorrhagic stroke/SE (HR 0.67 (95% CI 0.59 to 0.77)) and 0.65 (95% CI 0.50 to 0.86)) respectively, with no increase in major bleeding (HR 1.10 (95% CI 0.82 to 1.47)). NOAC use compared with VKA use was associated with lower risk of all-cause mortality and major bleeding (rates/100 patient-years 3.6 (95% CI 3.3 to 3.9) vs 4.8 (95% CI 4.5 to 5.2) and 1.0 (95% CI 0.9 to 1.1) vs 1.4 (95% CI 1.2 to 1.6); HR 0.79 (95% CI 0.70 to 0.89) and 0.77 (95% CI 0.61 to 0.98) respectively), with similar risk of non-haemorrhagic stroke/SE (rates/100 patient-years 0.8 (95% CI 0.7 to 0.9) versus 1.0 (95% CI 0.8 to 1.1); HR 0.96 (95% CI 0.73 to 1.25). Conclusion Important benefits in terms of mortality and major bleeding were observed with NOAC versus VKA with no difference among NOAC subtypes. Trial registration number NCT01090362.